Deva Holding stock, Deva Holding

Deva Holding stock: Company submits nine-month statements

Published on 11/18/2026 at 03:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Deva Holding stock follows the company's latest interim filing. The board approved unaudited consolidated statements covering January through September 2026.

Filing sets out nine-month position

  • The statements were prepared under Capital Markets Board rules and Turkish accounting standards.
  • Management said its review found no material misstatements or omissions that could make the disclosure misleading.
Deva Holding stock, Deva Holding, nine-month financial statements, pharmaceuticals, Turkey, Illustration mit AI erstellt.

Deva Holding approved and submitted unaudited consolidated financial statements for the nine-month period ended September 30, 2026, following a board decision on November 6. The filing was reported by TipRanks.

Interim filing covers first nine months

The statements cover the period from January 1 through September 30, 2026. They were prepared under Capital Markets Board rules and Turkish Accounting and Financial Reporting Standards, and were not reviewed by an independent audit firm.

Company representatives said they had reviewed the materials and found no material misstatements or omissions that could make the disclosure misleading. They also said the statements fairly present the company's assets, liabilities, financial position and results.

Healthcare portfolio spans global markets

Deva Holding develops and manufactures healthcare products, including human pharmaceuticals, active pharmaceutical ingredients and veterinary pharmaceuticals. The company serves more than 80 countries through its international network and operates manufacturing facilities approved under US FDA and EU GMP standards. Its portfolio covers therapeutic areas including cardiology, oncology, respiratory care and hematology.

Deva Holding at a glance

  • Company: Deva Holding A.S.
  • Reporting period: January 1 to September 30, 2026
  • Board approval: November 6, 2026
  • Statement status: Unaudited consolidated financial statements
  • Business: Human pharmaceuticals, active pharmaceutical ingredients and veterinary pharmaceuticals

Turkey's broader healthcare and pharmaceutical sector remains the relevant market environment; see current Turkey market reports.

More news and analyses on Deva Holding stock are available here.

Disclaimer...
en | boerse | 70529182 |